Long remissions in hairy cell leukemia with purine analogs

  title={Long remissions in hairy cell leukemia with purine analogs},
  author={Monica Else and Rosa Ruchlemer and Nnenna Osuji and Ilaria Del Giudice and Estella Matutes and Anthony C. Woodman and Andrew C. Wotherspoon and John G. Swansbury and Claire Dearden and Daniel Catovsky},
Both pentostatin and cladribine have efficacy in hairy cell leukemia (HCL), but it is not known which agent achieves better results. 

Hairy cell leukemia

Historically, the first treatment choices for hairy cell leukemia (HCL) were splenectomy and alpha‐interferon. Recently, purine analogues (pentostatin and cladribine) changed radically the treatment

Sustained long‐term remissions with weekly interferon maintenance therapy in hairy cell leukemia

Aim:  This study evaluates the efficacy of weekly α‐interferon (IFN) maintenance therapy in hairy cell leukaemia (HCL), a disease that remains incurable.

Time to Cure Hairy Cell Leukemia

  • I. LevyT. Tadmor
  • Medicine
    Turkish journal of haematology : official journal of Turkish Society of Haematology
  • 2017
First-line therapy for patients with HCL and even second- line therapy have not been substantially changed in the last 30 years.

The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia

The purine analogs pentostatin and cladribine have revolutionized the treatment of hairy cell leukemia (HCL) with overall responses in greater than 85% of patients and a median progression‐free

Hairy cell leukemia, blastic type: description of spleen morphology and immunophenotype of a distinctive case

Hairy cell leukemia (HCL) was first described in 1958 by Bouroncle et al., who named it leukemic reticuloendotheliosis, and introduced the term ‘hairy cell’ in 1966.

Hairy cell leukemia

The purpose of this review will be to establish the current status of HCL with respect to its pathophysiology, diagnosis, management, and future directions.

Historical aspects and milestones in the development of effective treatment for hairy cell leukemia

Immunoconjugate Therapy with BLZZ (anti-CDZZ antibody linked to truncated to Pseudomonas exotoxin) represents the newest milestone in the development of effective treatment for hairy cell leukemia.

Immunotoxins in the treatment of refractory hairy cell leukemia.

2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up

Repeat administration of 2-CdA is very effective in achieving a second CR and new agents such rituximab and BL22 were shown to be effective in the treatment of relapsed and refractory disease.

Current therapeutic options in hairy cell leukemia.

Although HCL has an indolent course, most patients will require treatment of the disease, and indications to initiate therapy include disease-related symptoms, signs of bone marrow failure, or frequent infections.



Phase II study of cladribine (2CDA) followed by rituximab for eradication of minimal residual disease (MRD) in hairy cell leukemia (HCL)

6620 Background: HCL is an indolent lymphoproliferative malignancy characterized by infiltration of the bone marrow, liver, and spleen by neoplastic B-cells with cytoplasmic hair-like projections. ...

Long term outcome of patients with hairy cell leukemia treated with pentostatin

Investigation of response and long term follow-up in HCL patients treated with pentostatin found pentosteratin to produce higher complete remission rates than IFN.

Comparison of pentostatin and alpha interferon in splenectomized patients with active hairy cell leukemia: an intergroup study. Cancer and Leukemia Group B and South-West Oncology Group.

  • K. Rai
  • Medicine, Biology
    Leukemia & lymphoma
  • 1994
It is shown that as compared to alpha interferon (aIF), pentostatin resulted in a higher incidence of response, but the difference was not statistically significantly, which confirms previous observations that both these agents have important place in therapy of hairy cell leukemia.

Cladribine in the treatment of hairy-cell leukaemia.

Long‐term follow‐up of patients with hairy cell leukaemia treated with pentostatin: lymphocyte subpopulations and residual bone marrow infiltration

Summary. Peripheral blood lymphocyte (PBL) subsets and bone marrow biopsies were analysed in six patients with hairy cell leukaemia (HCL) treated with 2′‐deoxycoformycin (pentostatin, DCF) according

Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.

These results confirm previous observations that single courses of cladribine administered to patients with HCL induce high response rates, the majority of which are CRs.

Rituximab, a chimaeric anti‐CD20 monoclonal antibody, in the treatment of hairy cell leukaemia

Rituximab appears promising in the treatment of HCL and warrants further studies.

Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients

Pentostatin is a highly effective regimen for hairy cell leukemia that produces durable complete responses and Subsequent malignancies do not appear to be increased with pentostatin treatment.

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.

BL22 can induce complete remissions in patients with hairy-cell leukemia that is resistant to treatment with purine analogues, including cladribine.

Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine.

2-chlorodeoxyadenosine may be the most effective therapy available for hairy-cell leukemia and its toxicity may be lower than that of deoxycoformycin, and the responses were achieved with single courses of treatment.